SecBot SecBot
Biotech Drug Report Generated Nov 6, 2026

amylin 355

NVO·NOVO NORDISK A S
NEUTRAL
Drug Impact Rating2/10
Trial phase
Phase 1/2
Time to market
Likely 5+ years away from potential approval, given the drug is in Phase 1/2 with no pivotal trials initiated or even designed yet.
Why 2/10
No hard, dated binary catalyst (PDUFA, pivotal readout, or AdComm) is scheduled for Amylin 355 in the next ~12 months. The drug is in Phase 1/2, the Phase I/II EU trial is still recruiting, and it represents a tiny fraction of Novo Nordisk's massive pipeline, so even a positive early readout would have negligible impact on NVO's share price.
Actionable Insight NEUTRAL

No near-term binary catalyst is scheduled for Amylin 355. The next meaningful event would be topline data from the Phase 1/2 EU trial (2026-526797-16-00), which is still recruiting 380 participants with a 26-week treatment period, so readout is likely 12-18+ months away. For NVO investors, this is a pipeline-watch item, not a near-term trading driver; the stock's direction will be set by CagriSema's FDA decision (expected around October 2026 per some sources), Wegovy/Zepbound competition, and broader obesity-market dynamics.

Price Chart

Loading chart...

Executive Summary

Amylin 355 (development code NNC0638-0355, also NN9638) is Novo Nordisk's once-weekly injectable amylin analogue in Phase 1/2 development for obesity. It mimics the natural satiety hormone amylin to promote weight loss through a pathway distinct from GLP-1 drugs like Wegovy. The drug is in very early clinical testing: a Phase 1 trial (NCT06577766) is active but no longer recruiting, and a Phase I/II EU trial (2026-526797-16-00) is still recruiting 380 participants with a 26-week treatment period. An oral tablet formulation is also being explored. For NVO investors, this is a distant pipeline asset with no near-term binary catalyst; the stock's trajectory will be driven by more advanced programs like CagriSema (awaiting FDA decision) and commercial dynamics of Wegovy and Ozempic.

How It Works

Amylin 355 is a synthetic version of amylin, a natural hormone produced by the pancreas that is released alongside insulin after meals. Amylin helps regulate appetite by slowing stomach emptying and signaling fullness to the brain. This drug is designed as a once-weekly injection to mimic these effects, promoting weight loss in people with obesity or overweight. It works through a different biological pathway than popular GLP-1 drugs like Wegovy, which is why it is being studied both as a standalone treatment and potentially in combination with GLP-1 drugs.

Trial Status

A Phase 1 first-in-human trial (NCT06577766) assessing safety, tolerability and pharmacokinetics of single and multiple subcutaneous doses in overweight or obese participants is active but no longer recruiting, last updated October 2026. A Phase I/II EU trial (2026-526797-16-00) is ongoing and recruiting, planning to enroll 380 participants to compare multiple doses of NNC0638-0355 versus placebo on body weight change over 26 weeks. An oral tablet formulation (NNC0638-0355 A 10217) is also in early-stage testing.

The Two-Sided Case

▲ Bull Case4
Amylin 355 targets the amylin receptor pathway, a distinct biological mechanism from GLP-1 that regulates satiety and energy metabolism, offering a potential complementary or alternative approach to existing obesity drugs like Wegovy.
Novo Nordisk is developing both injectable and oral (tablet) formulations of NNC0638-0355, expanding the potential delivery options and patient reach.
The global obesity drug market is projected to grow to tens of billions of dollars, and a differentiated once-weekly amylin analogue could capture meaningful share if it demonstrates a competitive efficacy/tolerability profile.
Novo Nordisk has deep expertise in peptide-based obesity therapies and a proven commercial infrastructure, giving Amylin 355 a strong development and launch pathway if successful.
▼ Bear Case4
Amylin 355 is very early-stage (Phase 1/2) with no published efficacy data; it is years away from any regulatory filing and could fail to show meaningful weight loss or acceptable tolerability in larger trials.
Novo Nordisk already has a more advanced amylin asset, cagrilintide (Phase 3 as monotherapy and in CagriSema), which underperformed Wegovy on weight loss in Phase 3, raising questions about the amylin class's standalone potential.
Eli Lilly is aggressively developing its own amylin assets and recently reported 20%+ weight loss with an amylin combination, intensifying competitive pressure in the obesity space.
As a tiny component of Novo Nordisk's massive pipeline (98 active Phase 1-3 trials per one tracker), even a positive Phase 1/2 readout for this drug would have negligible impact on NVO's share price.

Upcoming Catalysts

  • Topline data from the Phase 1 trial (NCT06577766), which is active but no longer recruiting, could emerge in 2027.
  • Completion of recruitment and eventual readout from the Phase I/II EU trial (2026-526797-16-00), which is still recruiting 380 participants with a 26-week treatment period, likely 12-18+ months away.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

NOVO NORDISK A S 6-K NVO ·Originating report

Sources · 10

Hover a chip for the title
1 adisinsight.springer.com2 pryzm.ozmosi.com3 synapse.patsnap.com4 ctis.eu5 clinicaltrials.eu6 adisinsight.springer.com7 cnbc.com8 fiercebiotech.com9 theraradar.com10 synapse.patsnap.com